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ABSTRACT
Background: Untreated HIV/AIDS leads to severe immune depletion with opportunistic 
infections and other co-morbidities. Highly active anti-retroviral therapy (HAART) 
enhances immunity by sustained HIV- viral suppression, increase in CD4+ cell 
count and immune restoration. HAART reduces risk of neutropaenia, anaemia and 
accompanied decrease in incidence of opportunistic infections. 
Objectives: To study the CD4+ cell response in patients with severe HIV/AIDS disease 
over one year period while on HAART.
Design: Observational, descriptive, longitudinal study.
Setting: Kisumu District Hospital (Medical outpatient clinic, medical and surgical 
wards), Nairobi Rhematology clinic and The Mater Hospital between July 2001 and 
March 2007.
Subjects: Four hundred and sixty three consenting patients were  screened for the 
study.
Intervention: The 103 patients included received HAART within one to four weeks 
and appropriate treatment for the opportunistic infections and other co-morbidities. 
Various HAART combinations including combivir/efavirenz, stavudine/lamivudine/
nevirapine and triomune 30/40 (fixed dose combination of stavudine, nevirapine and 
lamivudine) were used. Some delayed HAART because of the co- morbidities which 
had to be managed first (severe anaemia, hepatitis and meningitis).
Main outcome measures:  CD4+ cell increase, new clinical events.
Results: Four hundred and sixty three patients (256 males and 207 females) were 
screened. One hundred and three patients (55 males and 48 females) were included 
and 360 (201 males and 159 females) patients were excluded. Mean age was 37.9 ± 9.0 
years range of (15-70). The mean CD4+ cell counts over the study period were 141.7 
± 176.5 (1-1022), 192.4 ± 198.5 (3-1275), 221.2 ± 178.0 (3-1300), 247.2 ± 197.7 (1-1401) and 
268.6 ± 189.9 (1-1390) cells/µl at 0,3,6,9 and 12 months respectively. Nine patients had 
higher CD4+ cell counts > 350 cells/µl (433-1022) at baseline and higher HIV-viral RNA 
range between 51,830-1million copies/µl. The patients had multiple co-morbidities, 
namely, had tuberculosis, sepsis, cryptococcus meningitis, herpes zoster virus, four 
had non- Hodgkin’s lymphoma, oral candidiasis, hepatitis B virus, pneumocytis 
jiroveci pneumonia and HIV with renal dysfunction. Seventy (68%) patients had ≥ 2 
opportunistic infections. Mean AST, ALT and haemoglobin levels were 127.8 ± 79.8 
IU/L, 157.2 ± 50.1 IU/L and 9.1 ± 4.3 g/dl respectively. No patient tested positive for 
anti-HCV antibodies. 
S16 East african MEdical Journal December 2013 (Supplement) 
Conclusion: The majority of patients had advanced HIV infection at baseline.
There was a slow but steady increase in CD4+ cell count over one year. However only  
30(29.1%) of patients achieved immune restoration. Seventy three (70.9%) of patients 
still had immune depletion with low CD4+ cell counts at one year of receiving HAART. 
Patients with low CD4 + cell counts at baseline had a steady increase of CD4+ cells 
over the first six months and this emphasises the need to initiate HAART early in 
public health policy strategy. Expedited HAART initiation should be done in patients 
with CD4+ cell counts < 350 cells/µl. Delayed HAART, at low CD4+ cell counts, is 
associated with poor immune recovery/restoration. 
INTRODUCTION
Sub-Saharan Africa with fewer than 10% of the 
world’s total population accounts for 60% of HIV/
AIDS cases worldwide. The key feature of untreated 
HIV/AIDS infection is the progressive depletion of 
CD4+ cell lymphocytes, increased HIV viral RNA and 
resultant severe immunosuppression. The advent of 
highly active anti-retroviral therapy (HAART) in 1996 
profoundly changed positively the management of 
HIV/AIDS infections (1-5). Indeed, early initiation 
of HAART gives better clinical improvement (4, 5). 
HAART initiation leads to suppression of the HIV viral 
load to < 50 copies/μl, an increase in CD4+ cell count, 
dramatically decreases the incidence of opportunistic 
infections and leads to immune restoration ( partial 
or complete ), that is, reversal of HIV associated 
immunological alterations (3,7,8). This leads to a 
better quality of life of the patients (3-6). 
 The CD4+ cells are highly predictive of new 
AIDS events or death and enable the clinician to plan 
adequately for treatment (5, 6). Patients with advanced 
HIV disease, defined as those with CD4+ cell counts 
< 200 cells/μl, have a higher risk of progression of 
disease and opportunistic infections and other co-
morbidities. Lately, WHO has recommended CD4+ 
cell count < 350 cells/μl as the new threshold to 
initiate HAART (7).
 The study presents a cohort of HAART naïve 
patients with severe HIV disease and their subsequent 
CD4+ cell response to HAART over one year. It is 
noted that many studies do not include the very sick 
patients with HIV/AIDS in their protocols.
MATERIALS AND METHODS
A total of 463 (256 males and 207 females) consenting 
patients were screened for the study. Three hundred 
and sixty (201 males and 159 females) were excluded 
(referred to new Nyanza General Hospital other 
Mission Hospitals and health facilities offering free 
ART and care as they requested). One hundred 
and three patients (55 males and 48 females) were 
included. They were enrolled consecutively. They 
were able to be reviewed regularly for unscheduled 
medical attention and purchase ARTs (HAART was 
not universally available for all patients who were 
eligible). The patients were enrolled over a five year 
period (2001-2006) Table 2.
 The ethics and standards committee at the 
Kisumu District Hospital approved the study. A 
signed, informed consent was obtained from each 
patient, for < 18 years old, signed by parent or 
guardian. All the patients were physically examined 
by one of the authors (MDs).
 They included twenty four  patients with known 
HIV positive sero-status from peripheral voluntary 
counselling and testing (VCT) centres and not on 
HAART. Some were newly diagnosed cases of HIV 
infection and diagnostic counselling and testing (DCT) 
was done and post-test adherence counselling done 
and sustained. From each patient, biodata were taken; 
seven millilitres of blood was drawn under aseptic 
condition from the cubital fossa and divided into 
two aliquots of four millilitres and three millilitres 
respectively. Three millilitres whole blood was used to 
analyse CD4+ cell count by the FACS flow cytometry 
machine. The other four millilitres of blood was used 
to do ELISA test for HIV diagnosis (for new patients). 
The ELISA method has a sensitivity and specificity of 
99.9 and 98.9% respectively. The FACS flow cytometry 
machine has a sensitivity of 1-2000 cells/μl (FACS 
count machine from Baxton, Dickson).
 CD4+ cell count was done at zero month and 
then every three  months thereafter over one year 
period.  With the increasing numbers of ART centres 
countrywide, majority of patients were transferred 
to these patient support centres (PSCS). 
 The included patients self purchased HAART 
from the established hospital chemists. HAART was 
defined as a combination of three Anti-Retroviral 
Drugs Vis-À-Vis Combivir (Lamivudine plus 
Zidovudine) + Efavirenz or fixed dose combination of 
Nevirapine, Stavudine, Lamivudine (as EMTRI 30/40) 
or Stavudine, Lamivudine, Nevirapine/ Efavirenz, 
which were the combinations readily accessible as first 
line therapies. Seventy three patients were promptly 
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initiated on HAART within one week. 
 Thirty patients delayed initiation of HAART 
due to the severe co-morbidities which they had and 
had to be managed first ( nine, had severe anaemia, 
haemoglobin < 5g/dl, and received blood transfusion, 
13 had elevated AST and ALT and nine of whom had 
hepatitis B virus infection and had to be given Livolin, 
a hepatotonic drug for liver regeneration and five had 
meningitis and three encephalitis and were in coma 
and had to be managed).  
 The CD4+ cell count threshold of 350 cells/μl 
was chosen because, it is the lower normal limit in 
the guidelines and clinically represents a point below 
which opportunistic infections occur more frequently 
and HAART initiation is recommended.
Interventions: All patients had HAART initiated 
promptly (7-29 days). HAART was defined 
as a combination of three anti-retroviral 
drugs (efavirenz + combivir, EMTRI 30/40, or 
Lamivudine+Videx+Efavirenz). The opportunistic 
infections and other co-morbidities were appropriately 
managed as in– or out- patients. The patients were 
subsequently followed up by the authors (MDs).
Data Analysis: Data were analysed in a cohort of 
patients with symptomatic HIV disease and majority 
had low CD4+ cell counts less than 350 cells/μl. 
The data were cleaned and analysed using the SPSS 
(version 11). Missing values (four patients) were 
imputed using the individuals previous or last CD4+ 
cell count value to give the nearest estimated CD4 + 
cell count at follow up. Individual as well as group 
CD4+ cell count means were estimated using the 
ANOVA procedures and emerging trends plotted as 
a line graph on an excel sheet to show the variations 
for each category over the one year follow up period. 
The patients’ CD4+ cell counts were stratified as, < 200, 
200-349, 350-499 and > 500 cells/μl respectively.
RESULTS
Four hundred and sixty three patients (256 males 
and   207 females) were screened for the study. 
Three hundred and sixty patients were excluded and 
referred to other centres offering free HAART. (The 
study was conducted at a time when the government 
programme of free anti-retroviral drug access had not 
been fully rolled out).
 The 103 patients included (55 males and 48 
females) were enrolled and completed the study. The 
male: female ratio was 1.1:1. The mean age was 37.9 
± 9.0 years (range 15-70). Mean CD4+ cell count was 
141.7 ± 176.5 cells/μl (1-1022). 
 Ninety four (91.3%) patients had CD4+ cell 
counts < 350 cells/μl (1-330). Nine (8.7%) patients 
had CD4+cell counts > 350 cells/μl (433-1022 cells/
μl) and had HIV-RNA load done to enable rational 
initiation of HAART. Their HIV-viral RNA range were 
between 51,830- > 1 million copies/μl. HAART was 
initiated in these patients with high CD4+ cell count 
to preserve immunity. One patient died at eight weeks 
(CD4+ cell count of 13 cells/μl) due to pneumocystis 
jiroveci pneumonia. 
 The CD4+ cell count means and ranges every 
three months, Table 2. 
Figure 2 shows the graphical increase of the CD4+ 
cells over time.
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Figure 1 
Patient flow in the study
Number of patients 
Screened 
N = 463









Excluded 360 (Referred to)
Table 1
Demographic and laboratory profile of the 103 study patients at initiation of HAART.
Parameter Value(%, range)
M: F 55: 48 (1.1:1)
Mean Age (years) 37.9 ± 9.0 ( 15-70)
Mean haemoglobin (g/dl) 9.1 ± 4.3 (8.9-15)
CD4+ cell counts (cells/µl)
Mean CD4+ cell counts (350-1600 cells/μl) 141.7 ± 176.5 (1-1022)
> 500 4(4.0% ) patients
350-499 5(4.8%) patients
200-349 11(10.6% ) patients





AST(normal range - 5-40 IU/L) 127.8 ± 79.8
ALT(5-37 IU/L) 157.2 ± 50.1
Hepatitis B surface antigen 20(19.4%) patients
Anti-Hepatitis C virus status None
Creatinine ((normal range 60-120μmol/L) 100 ± 29.3 (59-176)
*CDC-Centres for Disease Control.
AST - Aspartate transaminase
ALT - Alanine transaminase
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Figure 2
Age group gender based distribution of patients with HIV who were seen at initiation of ART at the medical 
outpatients clinics during routine clinic follow-up
Figure 3
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Table 2
Mean CD4+ cell increase over 12 month period on HAART.
Time (Months) Mean CD4 +(Range) cells/μl
0 141.7 ± 176.5 (1-1022)
3 192.4 ± 198.5 (3-1275)
6 221.2 ± 178.0 (3-1300)
9 247.2 ± 197.7 (1-1401)
12 268.6 ± 189.9  (1-1390)
Figure 4
Trends of CD4+ cells counts among HIV patients initiated on HAART and followed up for twelve months
Table 3
Co-morbidities/opportunistic infections/conditions in a cohort of HIV positive, HAART naïve patients
Condition No.
Tuberculosis (pulmonary, extra-pulmonary) 17
Sepsis* 6
Cryptococcus Meningitis 10
Herpes Zoster Virus 7
Non-Hodgkin’s lymphoma 4
Oral Candidiasis 31
Hepatitis B Virus 20
Pneumocystis Jiroveci pneumonia 7
(HIV associated nephropathy) HIVAN 2
Severe anaemia (haemoglobin < 6.5 g/dl) 10
Sepsis (Pelvic Abscess 2,Ovarian abscess 1,Pyomyositis 2,Cervical region Abscess 1)
Follow-up period in months (at quarterly intervals)
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DISCUSSION
The study shows the CD4+ cell response in 
real clinical setting where patients have severe 
immunosuppression and > 1 co- morbidity. Use of 
HAART leads to suppression of HIV viral RNA, 
increase in CD4+ cell counts, decrease in opportunistic 
infections, a better quality of life and patients live 
longer (3-5). NASCOP recommends a CD4+ cell 
count of < 350 cells/μl as the threshold to initiate 
combined HAART (7).
 Absolute mean CD4+ cell counts at initiation 
of HAART was 141.7 ± 176.5 cells /μl (range 1-1022) 
and it increased to 192.4 ± 198.5 cells/μl (3-1275) 
at three months. This was an increase of mean of 
50.7 ± 22.0 cells/μl. Increase of CD4+ cell means in the 
subsequent months were 28.8, 26.0, and 21.4 cells/μl 
at 6th, 9th and 12th  months of therapy respectively. The 
subsequent intervals had smaller increments that were 
almost similar. Similar smaller marginal increases in 
CD4+ cell count after initiation of highly active anti-
retroviral therapy have also been noted in patients 
defined as incomplete responders in other studies 
(7-10). The mean CD4+ cell count at 12th month of 
therapy was 268.6 ± 189.9 (1-1390 cells/μl).
 It is also noted that patients in this study who 
had CD4+ cell counts of ≤ 100 cells/µl at initiation of 
HAART had an exponential increase in CD4+ cells 
over the next six months of treatment compared to 
those with CD4+ cell counts ≥ 200 cells/µl at initiation. 
This has a public health importance of advocating 
for prompt initiation of HAART and management 
of opportunistic infections to save the patients from 
deteriorating further. As evident in this cohort, most 
of the patients presented late to the patient support 
centres for HIV care.  
 Seventy three (70.9%) of patients had CD4+ 
cell count of < 350 (60-313 cells/μl) at the 12th 
month despite HAART and these are considered 
incomplete responders ( where CD4+ cell count has 
not normalised) with impaired immunity. 
 One study showed that an increase in CD4+ cell 
count of 99 cells/µl, in the first three months after 
initiating HAART in young patients, was associated 
with a complete response in five years. This parameter 
has a sensitivity and specificity of 80 and 72% 
respectively (baseline CD4+ T cell count X 6-monthly 
CD4+ cell increase/age) (9).  The initial slow increase 
of 50.7 ± 22.0 cells/μl in this cohort implies that the 
response was slow and the co-morbidities too could 
be one of the contributing factors, aside from therapy 
related factors like the type of HAART combination 
and adherence. 
 When immune recovery is impaired, even with 
virologically suppressive combination anti-retroviral 
therapy (cART), this means a longer time spent at low 
CD4+ cell counts, which substantially increases the 
risk for HIV-related morbidity and mortality (11).
 Indeed variable responses in this study could be 
due to multiple factors including: different HAART 
combinations, multiple co-morbidities including 
opportunistic infections, severe immunosuppression 
as depicted by the low mean CD4+ cell count, and 
undetermined viral factors. Adherence was not 
fully evaluated but is a probable confounder. This 
has implication on monitoring whether to do CD4+ 
cell counts three-monthly or six-monthly, or initial 
three-monthly then six-monthly.
 In this study, at the 12th month of therapy, 30 
(29.1%) patients had CD4+ cell count nadir >350 cells/
μl (350-1390 cells/μl) and thus achieved immune 
restoration/recovery and 73 (70.9%) patients still 
showed inadequate immune reserve/response, CD4 + 
cell count < 350 cells/μl at 12th month despite HAART 
and are defined as incomplete responders. 
 Incomplete responders have been characterised 
by older age, more advanced HIV infection (Lower 
CD4+ cell count at baseline), longer duration of HIV 
infection and higher plasma HIV -RNA levels (10, 12). 
Our HIV infected patients do not access healthcare 
for HIV infection adequately hence they present late 
with advanced HIV disease. 
 Influence of HAART on CD4+ cell responses has 
been evaluated in different settings and with regard 
to pathophysiology and was noted to give HIV/
AIDS patients better quality of life when there was 
a sustained HIV viral suppression (8,12-17)).
Nine patients had higher CD4+ cell counts > 350 
cells/μl and HAART was initiated because of their 
higher HIV-viral RNA load and to preserve immunity 
(14).
The CD4+ cell baseline level also predicts CD4+ cell 
response. Lower CD4+ cell counts, < 350 cells/μl was 
associated with a lower response to increase by 12% 
at four years compared to 46% response in CD4+ cell 
count of > 750 cells/μl at baseline. Older age groups 
and intravenous drug users have also been shown to 
be associated with lower CD4+ cell response (16). 
 Indeed other studies have shown that, although 
CD4+ cell count increases tend to be similar among 
patients receiving cART  regimen regardless of their 
CD4+ cell count at baseline, patients starting cART 
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with lower CD4+ cell counts are unable to reconstitute 
the CD4+ cell levels achieved by individuals who 
started anti-retroviral therapy at higher CD4+ cell 
counts even after three years of cART (18).
 The 30 (29.1%) of patients who achieved CD4+ 
cell count of > 350 cells/μl at 12th month are likely 
to be adequately protected against opportunistic 
infections. Initiating HAART at CD4+ cell count 
> 350cells/μl has been associated with fewer 
clinical events (opportunistic infections, Kaposi's 
Sarcoma, thrombocytopaenia, progressive multifocal 
leucoencephalopathy (PML), oral hairy leukoplakia, 
non-Hodgkins lymphoma, weight loss, herpes zoster 
virus, bacterial pneumonia, oral and oesophageal 
candidiasis, and cytomegalovirus and cervical 
dysplasia) during the immune reconstitution (IRIS) 
phase (14). 
 Late initiation of HAART is associated with 
incomplete CD4+ cell response which may affect 
long term prognosis, even in patients with good 
virologic control (8). In HAART naïve population, 
patients dying from HIV-1-infection are those who 
develop HIV-related complications before they are 
able to benefit from HAART-associated immune 
reconstitution and clinical stabilisation. This 
necessitates early HAART initiation.
 Seventy three patients in this study were 
promptly initiated on HAART with in one week. 
Thirty patients had co-morbidities (nine severe 
anaemia with haemoglobin < 5.0 g/dl and required 
blood transfusion; 13 had elevated transaminases, 
AST and ALT due to HBV infection in nine of them 
and non-viral causes five); five had meningitis (two 
bacterial and three cryptococcal) and three had 
encephalitis and were in coma). Managing these 
co-morbidities delayed HAART initiation for ten to 
fifteen days and also dictated choice of ARTs.
 The associated co-morbidities including 
infections, as observed in this cohort, may lower 
the response of CD4+ cells to HAART. In this study, 
73 (70.9%) patients had inadequate response with 
CD4+ cell counts of < 350 cells/μl at the 12th month 
of HAART.This compares with a study done in Paris 
which showed that between five and 27% of patients 
on HAART had low CD4+ cell counts after prolonged 
use of anti-retroviral drugs but successful viral 
suppression (18,19). Compared with control patients 
who had CD4+ cell counts above 500 cells/μl, and 
those with CD4+ cell counts less than 250 cells/μl, 
these patients with inadequate rise in CD4+ cell count 
rise had fewer naïve CD4+ T cells and lower thymic 
output due to thymus function impairment. They 
also had elevated levels of cell death by apoptosis 
compared to controls (17-19). 
 Other studies have also demonstrated that, 
in following up a cohort of HAART naïve HIV 
positive patients, the one year survival was 87% for 
adults and adolescents and 98% for children under 
13 years of age when put on HAART treatment. 
Indeed, the introduction of cART in industrialised 
countries in 1996 dramatically reduced the risk of 
AIDS-defining diseases and death, saving at least 
three million person-years of life during the first 
decade of it’s use in the United States alone (21 - 23). 
Without treatment, one year survival averages 30% 
in developing countries (24,25).
 A Thai study demonstrated that, even when 
initiated in late HIV/AIDS disease, HAART delivers 
clinical benefit. Mean CD4+ cell count in this study 
increased from 57 to 470 cells/μl over six years 
period in 74 patients (30). Thus, there is significant 
immunologic benefit associated with HAART and 
considerable impact on long term survival even in 
individuals who start HAART late and have AIDS-
defining infection.   
 In severely immunocompromised, anti-retroviral 
naïve, HIV- infected patients, treatment with an 
efavirenz-based regimen resulted in a superior 
virologic response compared with a non-boosted PI-
based regimen, with no difference in immunologic 
or clinical effectiveness (15).  Patients with very 
low CD4+ cell counts may therefore be initiated on 
effavirenz based HAART regimen as a first line. 
 Patients in this cohort presented late as evidenced 
by their low mean CD4+ cell counts. Patients in 
resource- constrained setting present late to HIV 
care clinics with severe immune dysfunction, low 
CD4+ cell counts, multiple opportunistic infections 
hence require prompt HAART initiation. Increased 
voluntary counselling and testing (VCT) use, 
enhanced and sustained public health education, 
and expanded comprehensive care clinics (CCC) in 
health institutions and widespread HIV screening 
could help identify patients early and initiate HAART 
before immune depletion is severe. The provision of 
government - funded HAART in public hospitals 
being rolled out by the ministry of health will 
encourage patients to present for VCT and initiate 
HAART early. Suffice it to note that VCT centres are 
underutilised. Public health education and VCT use 
must be stepped up and sustained. There is also an 
urgent need to develop and incorporate simple and 
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sustainable strategies for initiation and delivery of 
HAART without delay to large numbers of patients 
especially in the rural areas. HAART transforms 
the natural course of HIV infection by reducing 
morbidity and mortality and increasing CD4+ counts 
and suppression of HIV-viral RNA (19, 23-25). But 
how often should CD4+ cell count be alone in public 
health HAART programme?
 Indeed, in preventive HIV medicine, anti-
retroviral drugs reduce the infectivity of treated 
individuals by suppression of the HIV- viral load. 
It has been estimated in a cohort data that HAART 
reduces per-partnership infectivity by as much as 
60% (26-29).  
 Question arising from this study is that should 
first line HAART be the same in patients with 
HIV infection or should it be stratified for severity 
especially in public health intervention? What 
should the minimum level of additional support 
coopted to public HAART programme in view of 
late presentation? 
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